This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
421-01-02
A Phase 1/2, Adaptive, Multiple Dose-Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects with Thyroid Eye Disease (TED).
Overview
The 421-01-02 trial is testing a new potential treatment for Thyroid Eye Disease (TED).
Patients with TED can experience symptoms such as redness, irritation and swelling around the eyes.
The drug being investigated in this study is called Lonigutamab (previously known as VB421) and is an anti-IGF-1R monoclonal antibody which will be administered as a subcutaneous injection weekly for 12 weeks.
The main goal of this study is to learn how safe and tolerable Lonigutamab is, and also to assess its effectiveness of reducing TED symptoms.
As part of the study, suitable participants will be screened to determine their eligibility.
This study would require participants to attend CERA for a minimum of 11 visits for the 6-month duration of the trial.
For further information about this study please contact the Clinical Trials Research Centre on (03) 99298076 or email trials@cera.org.au.
- Principal Investigator
Dr Jwu Jin Khong
The 421-01-02 trial is testing a new potential treatment for Thyroid Eye Disease (TED).
Patients with TED can experience symptoms such as redness, irritation and swelling around the eyes.
The drug being investigated in this study is called Lonigutamab (previously known as VB421) and is an anti-IGF-1R monoclonal antibody which will be administered as a subcutaneous injection weekly for 12 weeks.
The main goal of this study is to learn how safe and tolerable Lonigutamab is, and also to assess its effectiveness of reducing TED symptoms.
As part of the study, suitable participants will be screened to determine their eligibility.
This study would require participants to attend CERA for a minimum of 11 visits for the 6-month duration of the trial.
For further information about this study please contact the Clinical Trials Research Centre on (03) 99298076 or email trials@cera.org.au.
- Principal Investigator
Learn More
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.